BioScience Trends
Online ISSN : 1881-7823
Print ISSN : 1881-7815
ISSN-L : 1881-7815

This article has now been updated. Please use the final version.

Liver transplantation for patients with hepatocellular carcinoma: Its current status and advances
Yasuhiko SugawaraTaizo Hibi
Author information
JOURNAL FREE ACCESS Advance online publication

Article ID: 2022.01199

Details
Abstract

Liver transplantation is one of the best treatment options for selected patients with hepatocellular carcinoma (HCC). The Milan criteria (a single tumor with a maximum size of 5 cm or two or three tumors with a maximum size of 3 cm without evidence of vascular or extrahepatic involvement or metastasis) are one of the most common criteria to select patients with HCC for transplantation, though they are considered too restrictive. A moderate expansion of the criteria has been found to yield comparable recurrence-free survival rates. HCC will recur in approximately 10% of patients, and mostly within the first 2 years after transplantation. The preoperative level of alpha-fetoprotein, macrovascular invasion, tumor size, and tumor number are prognostic factors for recurrence. Recurrence of HCC after transplantation results in a poor prognosis.

Content from these authors
© 2022 International Research and Cooperation Association for Bio & Socio-Sciences Advancement
feedback
Top